Argo Facility Issue and Investor Concerns Weighed on Ingredion
Cooke & Bieler said Ingredion detracted from its second-quarter strategy performance amid a resolved facility issue and mixed views on its acquisition bid.
Ingredion was the third-largest detractor in Cooke & Bieler’s Mid Cap Value Equity Strategy during the second quarter of 2026, the investment firm said in its investor letter. The stock closed at $96.46 on Sept. 29, according to the article.
Cooke & Bieler attributed soft earnings to an issue at Ingredion’s Argo facility, which the firm said has since been resolved. The letter did not specify the nature of the issue.
Investor concerns about potential volume pressure may also have weighed on the shares, according to the firm. It cited healthy-eating trends and the adoption of GLP-1 drugs as possible factors.
Cooke & Bieler said it believes Ingredion could benefit from demand for sugar reduction and protein fortification. It also noted that the company’s bid to acquire Tate & Lyle received mixed reviews from investors.
The strategy returned 8.05% in the quarter, below the Russell Midcap Value Index’s 13.4% return. Cooke & Bieler said an underweight in information technology drove nearly all of the strategy’s shortfall.
This article was produced with the help of AI technology.
Source: Yahoo Finance
